Goldman Sachs’s Ernexa Therapeutics ERNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-665
Closed -$3.31K – 6698
2026
Q1
$3.31K Buy
+665
New +$10.6K ﹤0.01% 6411
2025
Q2
– Sell
-48
Closed -$3.21K – 6169
2025
Q1
$3.21K Buy
48
+14
+41% +$1.73K ﹤0.01% 5999
2024
Q4
$3.77K Buy
+34
New +$9.22K ﹤0.01% 5960
2023
Q3
– Sell
-30
Closed -$25.5K – 5633
2023
Q2
$25.5K Buy
+30
New +$30.2K ﹤0.01% 5528
2022
Q4
– Sell
-10
Closed -$19K – 6054
2022
Q3
$19K Sell
10
-3
-23% -$10.3K ﹤0.01% 5948
2022
Q2
$48K Buy
13
+8
+160% +$57.4K ﹤0.01% 6033
2022
Q1
$79K Sell
5
-4
-44% -$75.9K ﹤0.01% 6171
2021
Q4
$293K Buy
9
+6
+200% +$326K ﹤0.01% 5681
2021
Q3
$182K Buy
+3
New +$259K ﹤0.01% 5754
2017
Q1
– Sell
-1
Closed -$112K – 6821
2016
Q4
$112K Hold
1
– – ﹤0.01% 6086
2016
Q3
$123K Hold
1
– – ﹤0.01% 6127
2016
Q2
$192K Buy
+1
New +$113K ﹤0.01% 5717
2016
Q1
– Hold
0
– – – 6695
2015
Q4
– Hold
0
– – – 6890
2015
Q3
– Hold
0
– – – 6912
2015
Q2
– Hold
0
– – – 7056
2015
Q1
– Hold
0
– – – 6742
2014
Q4
– Hold
0
– – – 6841
2014
Q3
– Hold
0
– – – 6907
2014
Q2
– Hold
0
– – – 6734
2014
Q1
– Hold
0
– – – 6647
2013
Q4
– Hold
0
– – – 6595

Other funds holding ERNA

Goldman Sachs's ERNA Position: Q2 2026 in Review

Goldman Sachs sold out of Ernexa Therapeutics (ERNA) in Q2 2026, closing a stake of 665 shares — an estimated $3.31K sold.

Goldman Sachs first reported a position in ERNA in Q2 2016 and held it in 12 quarters. The position peaked at $293K in Q4 2021. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

  • Goldman Sachs reported no remaining Ernexa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 665 Ernexa Therapeutics shares in Q2 2026, an estimated $3.31K.
  • Goldman Sachs first reported a position in Ernexa Therapeutics in Q2 2016 and held it in 12 quarters.
  • Goldman Sachs's Ernexa Therapeutics position peaked at $293K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Ernexa Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.